An arm of the European Medicines Agency (EMA) is recommending that Wayrilz (rilzabrutinib) be approved to treat adults with immune thrombocytopenia (ITP) who…
Thrombotic thrombocytopenic purpura
Thrombotic thrombocytopenic purpura is a rare, life-threatening blood disorder marked by dangerous clotting and low platelet counts. Prompt diagnosis and treatment are critical, and with proper care, most people recover and avoid serious complications.
While there’s no cure for immune thrombocytopenia, a range of treatments — from steroids to platelet-boosting therapies — can help manage symptoms. Choosing the right plan depends on platelet levels, bleeding risk, and individual health considerations.
Latest news
THROMBOTIC THROMBOCYTOPENIC PURPURA
NewsSwitching to Adzynma slashes hospital stays in congenital TTP
Switching from treatment with fresh frozen plasma (FFP) to Adzynma (ADAMTS13, recombinant-krhn) can help people with congenital thrombotic thrombocytopenic purpura (TTP) avoid hospital stays,…

